Trial reportJNCI cancer spectrum2026
Prevalence of patient-reported and clinician-graded cognitive symptomatic adverse events in older patients with advanced cancer.
Trial report in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
purposeCancer-related cognitive impairment is common in patients receiving cancer treatment but may be underdetected by clinician-graded adverse events (AEs) alone. Patient-reported outcomes and cognitive screening may improve identification of cognitive symptoms.
methodsWe conducted a secondary analysis of the nationwide, multicenter GAP70+ trial of adults aged ≥70 years with advanced cancer starting systemic therapy. Cognitive symptoms were assessed longitudinally using patient-reported and clinician-graded cognitive AEs, and Mini-Cog screening at baseline, 4-6 weeks, 3 months, and 6 months. We examined prevalence, longitudinal trajectories, and associations with Mini-Cog impairment. Statistical significance was set at 2-sided P < .05.
resultsAmong 704 participants (mean age = 77.2 years; range = 70-96 years), patient-reported cognitive AEs were more prevalent than clinician-graded cognitive AEs at all time points: 19% vs 0.48% at 4-6 weeks, 18% vs 2.5% at 3 months, and 22% vs 0.44% at 6 months (all P < .001). Patient-reported cognitive AEs also fluctuated within patients over time. Impaired Mini-Cog was associated with higher patient-reported cognitive AEs at all post-baseline time points: 31% vs 15% at 4-6 weeks, 34% vs 14% at 3 months, and 49% vs 15% at 6 months (all P < .001). In contrast, associations with clinician-graded cognitive AEs were observed only at 3 months (P = .004) and 6 months (P = .04).
conclusionsCognitive symptomatic AEs are common and often underdetected by clinician grading alone in older adults with advanced cancer. Combining patient-reported AEs with brief cognitive screening may improve detection during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.